Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter.

While 1H18 saw investors overweight in small- and mid-cap names, most buysiders now view those same companies as already expensive or getting there, meaning investors have to be even more selective to find companies that still have upside...